Calcium Antagonists for Duchenne Muscular Dystrophy

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2008 Oct 10

PMID 18843663

Citations 24

Authors

Margaret F Phillips

Rosaline Quinlivan

Affiliations

Soon will be listed here.

Abstract

Background: Duchenne muscular dystrophy (DMD) is a progressive muscle condition starting in childhood, leading to severe disability and a shortened life span. It is due to severe deficiency of the protein dystrophin which performs both structural and signalling roles within skeletal and cardiac myocytes. Calcium accumulates in dystrophic muscle cells and plays a role in cell damage. It has been hypothesised that use of calcium antagonists might reduce this calcium load and its toxic effect on muscle cells.

Objectives: To evaluate the effects of calcium antagonists on muscle function and muscle strength in people with DMD.

Search Strategy: The Cochrane Neuromuscular Disease Group Trials Register (February 2008), MEDLINE (from January 1950 to March 2008) and EMBASE (from January 1947 to March 2008) were searched. Search terms were 'calcium antagonists' or 'calcium channel blocker' or 'dantrolene' or 'verapamil' or 'nifedipine' or 'flunarizine' or 'diltiazem' or 'amlodipine' or 'nicardipine' and 'Muscular Dystrophy, Duchenne'. Bibliographies in reports of any trials were also searched.

Selection Criteria: All randomised or quasi-randomised controlled trials of any calcium antagonist in people with DMD.

Data Collection And Analysis: Both authors assessed all identified trials for inclusion in the study on the basis of whether they fulfilled the selection criteria. Both authors extracted data from the trials and assessed the methodological quality. Had there been more than one trial of the same intervention and outcome of sufficient methodological quality, we had planned to undertake a meta-analysis.

Main Results: Five randomised or quasi-randomised double-blind trials fulfilled the selection criteria, but were not sufficiently comparable to undertake a meta-analysis. The drugs studied were verapamil (8 participants), diltiazem (56 participants), nifedipine (105 participants) and flunarizine (27 participants). There were limitations in the description of blinding and randomisation, and definition of outcome measures. One trial, using verapamil, showed a difference between groups in muscle force measured by ergometry, but also revealed cardiac side effects. The numbers of people included in the trials were low, and so the studies may not have included enough people for sufficient power to detect small differences in muscle force or function between placebo and control groups. In addition, calcium antagonists were in an early stage of development and some of the second generation drugs that have a better side effect profile, such as amlodipine, have not been studied.

Authors' Conclusions: There is no evidence to show a significant beneficial effect of calcium antagonists on muscle function in DMD.

Citing Articles

Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia.

Aparicio P, Navarrete-Villanueva D, Gomez-Cabello A, Lopez-Royo T, Santamaria E, Fernandez-Irigoyen J J Cachexia Sarcopenia Muscle. 2024; 15(5):1883-1897.

PMID: 39009419 PMC: 11446689. DOI: 10.1002/jcsm.13539.

Targeting the DP2 receptor alleviates muscle atrophy and diet-induced obesity in mice through oxidative myofiber transition.

Ning H, Ren H, Zhao Y, Yin H, Gan Z, Shen Y J Cachexia Sarcopenia Muscle. 2022; 14(1):342-355.

PMID: 36527201 PMC: 9891918. DOI: 10.1002/jcsm.13136.

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Garegnani L, Hyland M, Roson Rodriguez P, Escobar Liquitay C, Franco J Cochrane Database Syst Rev. 2021; 12:CD013720.

PMID: 34850383 PMC: 8632644. DOI: 10.1002/14651858.CD013720.pub3.

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Garegnani L, Hyland M, Roson Rodriguez P, Escobar Liquitay C, Franco J Cochrane Database Syst Rev. 2021; 11:CD013720.

PMID: 34748221 PMC: 8574769. DOI: 10.1002/14651858.CD013720.pub2.

Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences.

Zablocka B, Gorecki D, Zablocki K Int J Mol Sci. 2021; 22(20).

PMID: 34681707 PMC: 8537421. DOI: 10.3390/ijms222011040.

References

Neglia D, Sambuceti G, Giorgetti A, Bartoli M, Salvadori P, Sorace O . Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure. J Cardiovasc Pharmacol. 2000; 36(6):744-50. DOI: 10.1097/00005344-200012000-00009. View

Wijeysundera H, Hansen M, Stanton E, Cropp A, Hall C, Dhalla N . Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J. 2003; 146(2):291-7. DOI: 10.1016/S0002-8703(03)00171-6. View

Zalman F, PERLOFF J, Durant N, CAMPION D . Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy. Am Heart J. 1983; 105(3):510-1. DOI: 10.1016/0002-8703(83)90371-x. View

Biggar W, Harris V, Eliasoph L, Alman B . Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006; 16(4):249-55. DOI: 10.1016/j.nmd.2006.01.010. View

Moxley 3rd R, Brooke M, Fenichel G, Mendell J, Griggs R, Miller J . Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine. Muscle Nerve. 1987; 10(1):22-33. DOI: 10.1002/mus.880100106. View

Scott O, Hyde S, Goddard C, Dubowitz V . Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve. 1982; 5(4):291-301. DOI: 10.1002/mus.880050405. View

Hudecki M, Pollina C, HEFFNER R . In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy. Exp Neurol. 1984; 84(3):512-23. DOI: 10.1016/0014-4886(84)90200-0. View

Roed A . Selective potentiation of subtetanic and tetanic contractions by the calcium-channel antagonist nifedipine in the rat diaphragm preparation. Gen Pharmacol. 1991; 22(2):313-8. DOI: 10.1016/0306-3623(91)90455-f. View

Mallouk N, Jacquemond V, Allard B . Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. Proc Natl Acad Sci U S A. 2000; 97(9):4950-5. PMC: 18338. DOI: 10.1073/pnas.97.9.4950. View

10.

Ozkul Y . Influence of calcium channel blocker drugs in neuromuscular transmission. Clin Neurophysiol. 2007; 118(9):2005-8. DOI: 10.1016/j.clinph.2007.06.002. View

11.

Petrof B, Shrager J, Stedman H, Kelly A, Sweeney H . Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993; 90(8):3710-4. PMC: 46371. DOI: 10.1073/pnas.90.8.3710. View

12.

Cornelio F, Dworzak F, Morandi L, Fedrizzi E, Balestrini M, Gondoni L . Functional evaluation of Duchenne muscular dystrophy: proposal for a protocol. Ital J Neurol Sci. 1982; 3(4):323-30. DOI: 10.1007/BF02043581. View

13.

Packer M, OConnor C, Ghali J, Pressler M, Carson P, Belkin R . Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996; 335(15):1107-14. DOI: 10.1056/NEJM199610103351504. View

14.

Bertorini T, Palmieri G, Griffin J, Igarashi M, Hinton A, KARAS J . Effect of dantrolene in Duchenne muscular dystrophy. Muscle Nerve. 1991; 14(6):503-7. DOI: 10.1002/mus.880140603. View

15.

Turturro F, Rocca B, Gumina S, De Cristofaro R, Mangiola F, Maggiano N . Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscul Disord. 2005; 15(8):532-40. DOI: 10.1016/j.nmd.2005.05.005. View

16.

Chang C, Lin S, Hong S, Chiou L . Neuromuscular block by verapamil and diltiazem and inhibition of acetylcholine release. Brain Res. 1988; 454(1-2):332-9. DOI: 10.1016/0006-8993(88)90834-7. View

17.

Rideau Y, Gatin G, Bach J, Gines G . Prolongation of life in Duchenne's muscular dystrophy. Acta Neurol (Napoli). 1983; 5(2):118-24. View

18.

Toifl K, Presterl E, Graninger W . [Ineffectiveness of diltiazem in Duchenne muscular dystrophy: a placebo-controlled double-blind study]. Wien Klin Wochenschr. 1991; 103(8):232-5. View

19.

Oberc M, Engel W . Ultrastructural localization of calcium in normal and abnormal skeletal muscle. Lab Invest. 1977; 36(6):566-77. View

20.

Kumar A, Khandelwal N, Malya R, Reid M, Boriek A . Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 2004; 18(1):102-13. DOI: 10.1096/fj.03-0453com. View